<DOC>
	<DOCNO>NCT00060684</DOCNO>
	<brief_summary>The aim trial determine appropriate dose pixantrone use combination obtain data combination 's safety activity profile .</brief_summary>
	<brief_title>Dose Ranging Trial Pixantrone FND-R Variant Regimen Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The FND-R regimen commonly use treatment indolent Non-Hodgkin 's lymphoma ( NHL ) contain chemotherapy agent mitoxantrone , fludarabine , dexamethasone ( steroid ) monoclonal antibody rituximab . In trial replace mitoxantrone pixantrone , agent similar chemical structure ( agent DNA intercalators ) . The trial run patient relapse refractory indolent NHL aim define appropriate dose pixantrone use combination , well obtain data pixantrone 's safety activity profile combination drug . This trial expect recruit 30 patient USA . Patients treated drug combination eight month follow closely four-week period last administration . After , patient receive physician check-ups every three month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion criterion Patients relapse refractory indolent ( lowgrade ) NHL Who receive 13 prior treatment chemotherapy Exclusion criterion Patients previously treat fludarabine Prior treatment rituximab ( Rituxan ) , unless complete response ( CR ) partial response ( PR ) treatment Patients know allergic reaction rituximab , murine protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Pixantrone</keyword>
	<keyword>BBR 2778</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>DNA Intercalator</keyword>
	<keyword>mitoxantrone</keyword>
	<keyword>fludarabine</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Mabthera</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>antibody</keyword>
	<keyword>NHL</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>indolent</keyword>
	<keyword>low grade</keyword>
	<keyword>Novuspharma</keyword>
</DOC>